- Home
- Products
- Customized ADCs
- CD22
- Anti-CD22 (hLL2)-SN-38 ADC
Anti-CD22 (hLL2)-SN-38 ADC (CAT#: ADC-W-093)
This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated (clone hLL2) via a linker to SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC payload drug
- Name
- CD22
- Alternative Names
- CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
- Target Entrez Gene ID
- 933
- Target UniProt ID
- P20273
- Overview
- CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
- Overview
- Humanized Anti-CD22-antibody, hLL2
- Generic name
- hLL2
- Species Reactivity
- Human
- Name
- SN-38 (7-ethyl-10-hydroxycamptothecin)
- Description
- SN38 (7-ethyl-10-hydroxy camptothecin) is an active metabolite of the cancer prodrug, irinotecan, with the ability of inhibiting Topoisomerase I, which is belong to the camptothecin family. SN-38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-FN1 (Radretumab)-SPDB-DM4 ADC (CAT#: ADC-W-1155)
- Anti-CD3E (Pasotuxizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2423)
- Anti-ERBB3 (Patritumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1122)
- Anti-ITGA4+ITGB7 (Crenezumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2502)
- Anti-CTLA4 (Ipilimumab)-SMCC-DM1 ADC (CAT#: ADC-W-998)
- Anti-FOLR1 (clone M9346A)-sulfo-SPDB-DM4 ADC (CAT#: ADC-W-402)
- Anti-IL6 (Enlimomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2250)
- Anti-CD22 (Inotuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2524)
- Anti-APP (Ponezumab)-SMCC-DM1 ADC (CAT#: ADC-W-710)
- Anti-CD70 (clone h1F6)-β-glucuronide-doxorubicin ADC (CAT#: ADC-W-376)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-093. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2526 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2525 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2528 | Anti-CD22-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2531 | Anti-CD22-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-484 | Anti-CD22 (clone hu10F4)-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2558 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2563 | Anti-MSLN (Anetumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2624 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2569 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.